Annual report pursuant to Section 13 and 15(d)

Statement of Stockholders??? Equity

v3.8.0.1
Statement of Stockholders’ Equity - USD ($)
Series A and Z Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total
Beginning balance, shares at Dec. 31, 2015 111,644 0      
Beginning balance, amount at Dec. 31, 2015 $ 112 $ 0 $ 3,441,352 $ (687,311) $ 2,754,153
Issuance of Series A Preferred Stock at $300 per share for cash, net of $12,500 issuance costs, shares 4,250        
Issuance of Series A Preferred Stock at $300 per share for cash, net of $12,500 issuance costs, amount $ 4   1,262,496   1,262,500
Shares issued in Gem transaction, net of issuance costs of $169,257, amount         0
Non-cash stock compensation         0
Net loss       (1,185,597) (1,185,597)
Ending balance, shares at Dec. 31, 2016 115,894 0      
Ending balance, amount at Dec. 31, 2016 $ 116 $ 0 4,703,848 (1,872,908) 2,831,056
Conversion of preferred stock to common stock, shares (115,894) 8,335,080      
Conversion of preferred stock to common stock, amount $ (116) $ 8,335 (8,219)   0
Issuance of common stock at $6 per share for cash, net of $32,400 issuance costs, shares   789,674      
Issuance of common stock at $6 per share for cash, net of $32,400 issuance costs, amount   $ 790 4,704,856   4,705,646
Tactic Pharma shares surrendered, shares   (2,888,727)      
Tactic Pharma shares surrendered, amount   $ (2,889) 2,889   0
Shares issued in Gem transaction, net of issuance costs of $169,257, shares   3,055,394      
Shares issued in Gem transaction, net of issuance costs of $169,257, amount   $ 3,055 18,329,310   18,332,365
Non-cash stock compensation     305,205   305,205
Net loss       (16,554,872) (16,554,872)
Ending balance, shares at Dec. 31, 2017 0 9,291,421      
Ending balance, amount at Dec. 31, 2017 $ 0 $ 9,291 $ 28,037,889 $ (18,427,780) $ 9,619,400